255 related articles for article (PubMed ID: 34024024)
1. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Waddington-Cruz M; Wixner J; Amass L; Kiszko J; Chapman D; Ando Y;
Neurol Ther; 2021 Dec; 10(2):753-766. PubMed ID: 34024024
[TBL] [Abstract][Full Text] [Related]
2. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
3. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
[TBL] [Abstract][Full Text] [Related]
4. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
Dispenzieri A; Coelho T; Conceição I; Waddington-Cruz M; Wixner J; Kristen AV; Rapezzi C; Planté-Bordeneuve V; Gonzalez-Moreno J; Maurer MS; Grogan M; Chapman D; Amass L;
Orphanet J Rare Dis; 2022 Jun; 17(1):236. PubMed ID: 35717381
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS.
Gentile L; Tournev I; Amass L; Chapman D; Mazzeo A;
Cardiol Ther; 2021 Dec; 10(2):481-490. PubMed ID: 34148211
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Campbell CM; LoRusso S; Dispenzieri A; Kristen AV; Maurer MS; Rapezzi C; Lairez O; Drachman B; Garcia-Pavia P; Grogan M; Chapman D; Amass L;
Cardiol Ther; 2022 Sep; 11(3):393-405. PubMed ID: 35583798
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
[TBL] [Abstract][Full Text] [Related]
10. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
11. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
12. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Kristen A; Wixner J; Diemberger I; Gonzalez-Moreno J; Cariou E; Maurer MS; Planté-Bordeneuve V; Garcia-Pavia P; Tournev I; Gonzalez-Costello J; Duarte AG; Grogan M; Mazzeo A; Chapman D; Gupta P; Glass O; Amass L;
Orphanet J Rare Dis; 2023 Nov; 18(1):350. PubMed ID: 37946256
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Dispenzieri A; Grogan M; Coelho T; Tournev I; Waddington-Cruz M; Wixner J; Diemberger I; Garcia-Pavia P; Chapman D; Gupta P; Glass O; Amass L;
Cardiol Ther; 2024 Mar; 13(1):117-135. PubMed ID: 38117424
[TBL] [Abstract][Full Text] [Related]
15. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Waddington-Cruz M; Ando Y; Amass L; Kiszko J; Chapman D; Sekijima Y;
J Peripher Nerv Syst; 2021 Jun; 26(2):160-166. PubMed ID: 33844361
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Damy T; Kristen AV; Suhr OB; Maurer MS; Planté-Bordeneuve V; Yu CR; Ong ML; Coelho T; Rapezzi C;
Eur Heart J; 2022 Feb; 43(5):391-400. PubMed ID: 30938420
[TBL] [Abstract][Full Text] [Related]
19. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease.
Wixner J; Mundayat R; Karayal ON; Anan I; Karling P; Suhr OB;
Orphanet J Rare Dis; 2014 Apr; 9():61. PubMed ID: 24767411
[TBL] [Abstract][Full Text] [Related]
20. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]